Results 251 to 260 of about 8,198,133 (306)
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source
Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling. [PDF]
Ye P+17 more
europepmc +1 more source
Pericytes change function depending on glioblastoma vicinity: emphasis on immune regulation
Pericytes alter their transcriptome depending on their proximity to the tumor core. In the tumor core, pericytes display a more active state with higher communication strength but with lower immune activation potential and a shift toward extracellular matrix production.
Carolina Buizza+5 more
wiley +1 more source
Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma. [PDF]
Junkuhn C+14 more
europepmc +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source
Predicting Mechanosensitive T Cell Expansion from Cell Spreading. [PDF]
Wang X+6 more
europepmc +1 more source
The T cell receptor sequence influences the likelihood of T cell memory formation. [PDF]
Lagattuta KA+7 more
europepmc +1 more source
T cell-derived small extracellular vesicles in cancer-immune interactions. [PDF]
Garcia MJC+3 more
europepmc +1 more source
A dual nature of γδ T cell immune memory responses. [PDF]
Suen TK+5 more
europepmc +1 more source
T Cell Resistance: On the Mechanisms of T Cell Non-activation. [PDF]
Beckers D+3 more
europepmc +1 more source